Every article, report, and earnings note where RXRX appears.
Keith Kohl of Angel Publishing's Topline Trader is promoting “Nvidia's Secret Partner,” also known as the “AI Doctor” pitch. We identify the company and test the claims.
Nanyang Biologics is an AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers exposure to a preclinical platform at a $1.5 billion headline value, but shareholders should watch redemptions, dilution, and whether the deal closes with enough cash.
Keith Kohl of Angel Publishing’s Topline Trader is promoting “AI Doctor,” a pitch built around an AI drug-discovery biotech. The filings support the company match, but not several of the ad’s biggest claims.
GNQ Insilico is a TechBio and precision-medicine company going public through a merger with IB Acquisition Corp. (Nasdaq: IBAC), with the deal originally expected to close in Q3 2026. The bull case is an AI-driven drug discovery platform; the bear case is a small trust, heavy financing dependence, and meaningful dilution risk.
This countdown spans AI-native drug discovery, computational chemistry, genomics, diagnostics, antibody platforms and data-rich biotech businesses.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate RXRX ReportCancel anytime